Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography

Abstract 

The augmentation effect of (–)pindolol as used in combination with SSRI to treat major depression has been ascribed to blocking of dorsal raphe nucleus cell body 5-HT autoreceptors. In this study, the radioligand [carbonyl-11C]WAY-100635 and positron emission tomography were used to establish whether pindolol at a clinical dose level (10 mg s.o.d.) occupies 5-HT1A receptors in the human brain in vivo. Three healthy males were recruited and each subject was used as his own control. The 5-HT1A receptor occupancy was calculated for the frontal and temporal cortex and the raphe nuclei, using and a ratio analysis with the cerebellar cortex as the reference region. Maximal pindolol plasma concentration was reached within 3 h after drug administration. Two hours after pindolol administration, the regional 5-HT1A receptor occupancy was within the range 7–21% in the three subjects. The study confirms that the 5-HT1A-receptor may be a clinically significant target for pindolol.

This is a preview of subscription content, access via your institution.

Author information

Affiliations

Authors

Additional information

Received: 8 March 1999 / Final version: 15 March 1999

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Andrée, B., Thorberg, SO., Halldin, C. et al. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology 144, 303–305 (1999). https://doi.org/10.1007/s002130051009

Download citation

  • Key words Positron emission tomography
  • [Carbonyl-11C]WAY-100635
  • Human 5-HT1A receptor
  • Pindolol pharmacokinetics